Pharmaron Beijing : SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2019

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Pharmaron Beijing Co., Ltd.*

康龍化成（北京）新藥技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2019

Reference is made to the annual report for the year ended December 31, 2019 (the "Annual Report") of Pharmaron Beijing Co., Ltd.* (康龍化成（北京）新藥技術股份有限公司) (the "Company") published on April 23, 2020. Unless otherwise stated, the terms used in this announcement shall have the same meanings as defined in the Annual Report.

USE OF PROCEEDS FROM THE GLOBAL OFFERING

As disclosed in the Annual Report, the Company raised net proceeds of approximately RMB4,522.7 million from the Global Offering of its H Shares and such net proceeds have not been utilized as at December 31, 2019. In addition to the information disclosed under the section headed "USE OF PROCEEDS FROM THE GLOBAL OFFERING" in the Annual Report, the Company would like to provide further information regarding the expected timeline for utilizing the net proceeds from the Global Offering, details of which are set out as follows:

	Allocation of
	net proceeds	Utilized	Utilized	Expected timeline
	as disclosed	amount	amount as	for utilizing the
	in the Annual	as at	of the date of	net proceeds from
	Report	December 31,	the Annual	the Global
Use of proceeds	(RMB million)	2019	Report	Offering (Note)
Expand capacities and	1,356.8	-	- Expected to be fully
capabilities in laboratory				utilized by December
and manufacturing				31, 2021
facilities in the PRC
- investing in upgrading	881.9	-	- Expected to be fully
and expanding our Ningbo				utilized by December
facility				31, 2021
- investing in upgrading	203.5	-	- Expected to be fully
and expanding our Tianjin				utilized by December
facility				31, 2021
- investing in upgrading	271.4	-	- Expected to be fully
and expanding other				utilized by December
manufacturing facilities				31, 2021

1

	Allocation of
	net proceeds	Utilized	Utilized	Expected timeline
	as disclosed	amount	amount as	for utilizing the
	in the Annual	as at	of the date of	net proceeds from
	Report	December 31,	the Annual	the Global
Use of proceeds	(RMB million)	2019	Report	Offering (Note)
Fund further expansion of	452.3	-	- Expected to be fully
businesses in the U.S. and				utilized by December
U.K.				31, 2021
Establish pharmaceutical	904.5	-	- Expected to be fully
R&D services platform for				utilized by December
discovery and development				31, 2022
of biologics
Expand clinical development	678.4	-	- Expected to be fully
services				utilized by December
				31, 2022
Expand our capacity and	678.4	-	- Expected to be fully
capabilities through				utilized by December
potential acquisitions of				31, 2022
CRO and CMO companies
and businesses
General corporate and	452.3	-	- Expected to be fully
working capital				utilized by December
				31, 2020
Total	4,522.7	-	-

Note: The Company intends to use the remaining unused net proceeds in the coming years in accordance with the purpose set out in the Prospectus. The Company will continue to evaluate the Group's business objectives and will change or modify the plans against the changing market conditions to suit the business growth of the Group. We will issue an appropriate announcement if there is any material change to the above proposed use of proceeds.

2

The supplementary information provided in this announcement does not affect other information contained in the Annual Report, and save for the additional information disclosed above, the contents of the Annual Report remain unchanged.

By order of the Board

Pharmaron Beijing Co., Ltd.*

康龍化成（北京）新藥技術股份有限公司

Chairman

Dr. Lou Boliang

Beijing, the PRC

August 11, 2020

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Chen Pingjin, Mr. Hu Baifeng, Mr. Li Jiaqing and Mr. Zhou Hongbin as non-executive Directors; Mr. Dai Lixin, Ms. Chen Guoqin, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.

• For identification purposes only

3